ADCYAP1 is a member of the circadian entrainment pathway and considered a potential target for therapies to ameliorate drug abuse, migraine, stress-related psychopathologies and inflammatory diseases [69, 73–78]. Here, ADCYAP1 is linked to migraine disorder.